Celgene
Search results
1 day ago · Companies like Juno Therapeutics, Tessa Therapeutics, and Adaptimmune are leading the way in this field, with TT-02 and other CAR T-cell therapies showing promise for the treatment of various cancers.
Jun 22, 2024 · Orvacabtagene Autoleucel: a BCMA modulators, Immunologic cytotoxicity, T lymphocyte replacements Drug, Initially developed by Juno Therapeutics, Inc.,
4 days ago · Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that it has received...
Jun 17, 2024 · June 17, 2024. Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma. Author (s): Gina Mauro. Conference | European Hematology Association Congress. Listen. Key...
4 days ago · Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill ...
Jun 27, 2024 · HIV-1 prevention and control strategies harnessing NK cells could be enabled by mechanistic understanding of how NK cells recognize HIV-infected T cells. Here, we profiled the phenotype of human primary NK cells responsive to autologous HIV-1-infected CD4+ T cells in vitro.
Jun 10, 2024 · On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy.
